Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans
Each vial contains 10mg of high-purity Epitalon with a verified purity of 99%, helping support consistency and reliability across research applications
IGF1 is anabolic and growth-stimulating, so theres a potential risk that it can induce tumour growth [8]
Mieusset R, Bengoudifa B, Bujan L
The shelf life after the bottle has been puncture for the first time is 28 days from that date
Clinical Benefits Protects and heals the gastrointestinal tract, supporting gut lining integrity and helping address inflammatory bowel conditions and digestive issues
